MedTrace Logo

Anlotinib in Metastatic HER2 Negative Breast Cancer

NCT04002284 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2020-07-29

No results posted yet for this study

Summary

The hypothesis of this study is to discover if the anlotinib can shrink or slow the growth of pretreated HER2 negative metastatic breast cancer.

Conditions

  • Breast Neoplasm
  • Antineoplastic Agents
  • Anlotinib

Interventions

DRUG

Anlotinib Hydrochloride

Anlotinib 12mg p.o. d1-14, 21days/cycle

Sponsors & Collaborators

  • Peng Yuan

    lead UNKNOWN

Principal Investigators

  • Peng Yuan · Chinese Academy of Medical Sciences

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-12
Primary Completion
2020-01-10
Completion
2020-03-15

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04002284 on ClinicalTrials.gov